Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovail Lab Int SrlfiledCriticalBiovail Lab Int Srl
Priority to ARP070105745priorityCriticalpatent/AR064466A1/en
Publication of AR064466A1publicationCriticalpatent/AR064466A1/en
Composiciones, formulaciones y medicamentos farmacéuticos que comprenden una sal de bupropion en particular tabletas de liberacion modificada que comprenden una cantidad efectiva de hidrobromida de bupropion y el uso de la sal de bupropion para preparar un medicamento para tratar una condicion. Reivindicacion 60: La composicion de la reivindicacion 1 que comprende además un segundo fármaco. Reivindicacion 66: La composicion de la reivindicacion 60 en la que dicho segundo fármaco es citalopram. Reivindicacion 67: La composicion de la reivindicacion 60 en la que dicho segundo fármaco es escitalopram. Reivindicacion 68: La composicion de la reivindicacion 60 en la que el segundo fármaco es venlafaxina.Compositions, formulations and pharmaceutical medicaments comprising a bupropion salt in particular modified-release tablets comprising an effective amount of bupropion hydrobromide and the use of bupropion salt to prepare a medicament for treating a condition. Claim 60: The composition of claim 1 further comprising a second drug. Claim 66: The composition of claim 60 wherein said second drug is citalopram. Claim 67: The composition of claim 60 wherein said second drug is escitalopram. Claim 68: The composition of claim 60 wherein the second drug is venlafaxine.
ARP0701057452007-12-192007-12-19
FORMULATIONS OF A MODIFIED LIBERATION BUPROPION SALT
AR064466A1
(en)
Pharmaceutical composition comprising acetaminophen and a complex tramadol material, which exhibits a sustained and coordinated release through a sustained release and an immediate release layer; method of preparation; and the use of a complex material of tramadol and acetaminophen to prepare a medication for the treatment of pain.
COMPOUNDS DERIVED FROM SULFONIL-FENIL-2H- [1,2,4] OXADIAZOL-5-ONA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; PREPARATION PROCEDURE; AND USE OF THE COMPOUND IN THE TREATMENT OF METABOLISM DISORDERS, AS DIABETES MELLITUS, DIS
PHARMACEUTICAL COMPOSITION THAT INCLUDES A COMPOUND DERIVED FROM PIRAZOL-O-GLUCOSIDE COMBINED WITH AT LEAST A SECOND THERAPEUTIC AGENT; AND USE OF THE COMPOSITION FOR THE TREATMENT OF MELLITUS DIABETES, CATARATS, NEUROPATHY, MYOCARDIAL INFARTS, AND
Compounds derived from [2,1,3] benzoxadiazole-5-carboxamides, modulators of ampa receptors; pharmaceutical compositions; and its use in the treatment of hypoglutamatergic conditions, cognitive disorders, parkinson's disease, adhd, rett syndrome, respiratory depression, fragile x syndrome, and Alzheimer's disease.
PHARMACEUTICAL COMPOSITION THAT INCLUDES A CHITOSAN, A COSMETIC OR PHARMACEUTICAL ACTIVE INGREDIENT, AND A VOLATILE SOLVENT; AND ITS USE TO TREAT PSORIASIS, MICOSIS BETWEEN OTHER DISEASES.
PHARMACEUTICAL COMPOSITION, PRODUCT AND TREATMENT METHOD FOR A COGNITIVE DISORDER AND USES OF AN ACETILCOLINESTERASE INHIBITOR AND A 5- HT6 ANTAGONIST IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF A COGNITIVE DISORDER
COMPOUNDS DERIVED FROM BENZOPIRAZOLES; PROCESS FOR THE PREPARATION OF SUCH COMPOUNDS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS AND ANOTHER ACTIVE AGENT; AND ITS USE FOR THE TREATMENT OF ASTHMA, INFLAMMATION, AMONG OTHER DISEASES.
ORAL PHARMACEUTICAL COMPOSITION INCLUDING LEVODOPA IN A UNIT DOSE OF AROUND 100 TO AROUND 500 MG AND AN ADEQUATE EXCIPIENT; AND ITS USE TO TREAT PARKINSON.
Oral solid pharmaceutical composition comprising a) a 2-amino-2- [2- (4-octyl-phenyl) -ethyl] -propane-1,3-diol (fingolimod) compound in an amount of 0.5 mg or less , or a salt thereof, b) a filler and c) a stabilizer comprising a cyclodextrin; and its use to treat an autoimmune disease such as multiple sclerosis.